LONG BEACH, Calif. - Obagi Medical Products, Inc. (Obagi) announced today that it is providing an unrestricted grant to the American Society of Plastic Surgeons for research on new and improved therapies to enhance healing and patient outcomes. It is hoped that the study of pre- and post-skin conditioning of ablative laser procedures will result in potentially shortened healing rates, reduced adverse events, and less visible scarring. The research may also help identify techniques that may enhance outcomes of those using such products for cosmetic therapeutic purposes. "This is the first carefully constructed and monitored study conducted to measure results of pre- and post-treatment of the skin," said Brian Kinney, MD, president of the Plastic Surgery Educational Foundation, the research arm of ASPS. "We hope this research will validate anecdotal evidence that such treatment can reduce side effects such as redness and darkening of the skin while enhancing longer-lasting cosmetic results."
Initial study findings are expected to be released at the ASPS annual meeting in San Francisco in October 2006.
"We are honored to have the opportunity to create such a strong relationship with ASPS," said Steve Carlson, Obagi President and CEO. "This collaboration represents an ideal way for both organizations to focus on the science of wound healing and skin health."
The significance of these clinical trials is underscored by the estimated 9.2 million procedures performed by plastic surgeons in 2004, and all indications suggest that these procedures continue to grow at a significant rate.
About Obagi Medical Products, Inc.
Obagi is a specialty pharmaceutical company that develops and commercializes innovative skin health products for the dermatology, plastic surgery, and related Aesthetic and Therapeutic markets. Obagi's products are uniquely designed to improve penetration of drug agents across the skin barrier for the prevention and correction of the most common and visible skin disorders in adult skin such as chloasma, melasma, senile lentigines, acne vulgaris and sun damage. Obagi launched its first skincare system, Obagi Nu-Derm, in 1988; and in 2004 launched the first and only prescription strength Vitamin C and hydroquinone system, Obagi-C Rx. Obagi launched a new line of Professional-C Serums, at the recent ASPS conference in Chicago, in concentrations of 5%, 10%, 15%, and 20% L-ascorbic acid to provide a range of antioxidant treatments to patients. Obagi System products are only available through physicians, which include over 3,500 in the U.S., primarily Plastic Surgeons and Dermatologists.
About American Society of Plastic Surgery (ASPS)
The American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world. With more than 6,000 members, the society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises 90 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.
Print this page